Status:
COMPLETED
Metyrapone as Additive Treatment in Major Depression
Lead Sponsor:
Universitätsklinikum Hamburg-Eppendorf
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to test whether metyrapone is an effective and safe augmenting agent in the treatment of major depression.
Detailed Description
The investigators' understanding of the neuroendocrine pathophysiology of depression has made significant progress in recent years, which should help to develop new remedies. Alterations of the hypoth...
Eligibility Criteria
Inclusion
- Diagnosis of major depressive disorder; single or recurrent according to DSM-IV criteria (296.2 or 296.3)
- A minimum baseline Hamilton score of 18 points on the Hamilton Rating Scale for Depression (HamD; 21-item version)
- Age from 18 to 75 years
- A drug free period of at least 5 days from antidepressants, antipsychotics, mood stabilizers and all other medications except for mild antihypertensive agents
- A negative urinary drug screening diagnosis
Exclusion
- A current DSM-IV diagnosis for other axis I psychiatric disorders
- Serious medical conditions, especially those associated with adrenal insufficiency
- Pregnancy, nursing or refusal to use a reliable method of birth control in women.
- Participants were randomly assigned to a study group if they met these criteria.
Key Trial Info
Start Date :
May 1 1998
Trial Type :
INTERVENTIONAL
End Date :
July 1 2001
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT00125554
Start Date
May 1 1998
End Date
July 1 2001
Last Update
August 12 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dept. of Psychiatry and Psychotherapy, UKE
Hamburg, Hamburg, Germany, 20246